Helping colorectal cancer survivors benefit from changing lifestyle behaviors: Implementation science and private industry collaboration to the rescue
Menée aux Etats-Unis à partir de données portant sur 992 patients atteints d'un cancer du côlon de stade III, cette étude de cohorte prospective analyse l'association entre l'adhésion aux recommandations relatives à la nutrition et à la pratique d'une activité physique, et la survie sans maladie, la survie sans récidive et la survie globale
About 20 years ago, investigators working in the National Cancer Institute (NCI) cooperative group system sought to prove that a novel adjuvant therapy regimen would extend the overall survival of patients with stage III colorectal cancer. The CALGB 89803 study compared weekly administration of irinotecan plus fluorouracil and leucovorin vs the standard care at the time, fluorouracil plus leucovorin. Unfortunately, this trial had negative results, and the investigational arm was far more toxic than the standard care.1 The report by Van Blarigan et al2 represents a cancer control gem that came out of the ashes of this trial.
JAMA Oncology , éditorial, 2017